Digoxin immune fab treatment for severe preeclampsia

C. David Adair, Vardaman M. Buckalew, Steven W. Graves, Garrett K. Lam, Donna D. Johnson, George Saade, David F. Lewis, Christopher Robinson, Theodore M. Danoff, Nikhil Chauhan, Moana Hopoate-Sitake, Kathy B. Porter, Rachel G. Humphrey, Kenneth F. Trofatter, Erol Amon, Suzanne Ward, Lizbeth Kennedy, Lorrie Mason, J. Andrew Johnston

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF (n=24) or placebo (n=27) for 48 hours. Primary outcomes were change in creatinine clearance (CrCl) at 24 to 48 hours and antihypertensive drug use. Serum sodium pump inhibition, a sequela of endogenous digitalis-like factors (EDLF), was also assessed. CrCl in DIF subjects was essentially unchanged from baseline versus a decrease with placebo (310 and 3410 mL/min, respectively, p=0.02). Antihypertensive use was similar between treatments (46 and 52%, respectively, p=0.7). Serum sodium pump inhibition was decreased with DIF compared with placebo at 24 hours after treatment initiation (least squares mean difference, 19 percentage points, p=0.03). DIF appeared to be well tolerated. These results suggest DIF prevents a decline in renal function in severe preeclampsia by neutralizing EDLF. Sodium pump inhibition was significantly improved. Further research is warranted.

Original languageEnglish (US)
Pages (from-to)655-662
Number of pages8
JournalAmerican Journal of Perinatology
Volume27
Issue number8
DOIs
StatePublished - 2010

Fingerprint

Pre-Eclampsia
Sodium-Potassium-Exchanging ATPase
Placebos
Antihypertensive Agents
Creatinine
Therapeutics
Least-Squares Analysis
Serum
digoxin antibodies Fab fragments
Kidney
Safety
Research

Keywords

  • Digoxin immune Fab
  • endogenous digitalis-like factors
  • preeclampsia
  • sodium pump

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Cite this

Adair, C. D., Buckalew, V. M., Graves, S. W., Lam, G. K., Johnson, D. D., Saade, G., ... Johnston, J. A. (2010). Digoxin immune fab treatment for severe preeclampsia. American Journal of Perinatology, 27(8), 655-662. https://doi.org/10.1055/s-0030-1249762

Digoxin immune fab treatment for severe preeclampsia. / Adair, C. David; Buckalew, Vardaman M.; Graves, Steven W.; Lam, Garrett K.; Johnson, Donna D.; Saade, George; Lewis, David F.; Robinson, Christopher; Danoff, Theodore M.; Chauhan, Nikhil; Hopoate-Sitake, Moana; Porter, Kathy B.; Humphrey, Rachel G.; Trofatter, Kenneth F.; Amon, Erol; Ward, Suzanne; Kennedy, Lizbeth; Mason, Lorrie; Johnston, J. Andrew.

In: American Journal of Perinatology, Vol. 27, No. 8, 2010, p. 655-662.

Research output: Contribution to journalArticle

Adair, CD, Buckalew, VM, Graves, SW, Lam, GK, Johnson, DD, Saade, G, Lewis, DF, Robinson, C, Danoff, TM, Chauhan, N, Hopoate-Sitake, M, Porter, KB, Humphrey, RG, Trofatter, KF, Amon, E, Ward, S, Kennedy, L, Mason, L & Johnston, JA 2010, 'Digoxin immune fab treatment for severe preeclampsia', American Journal of Perinatology, vol. 27, no. 8, pp. 655-662. https://doi.org/10.1055/s-0030-1249762
Adair, C. David ; Buckalew, Vardaman M. ; Graves, Steven W. ; Lam, Garrett K. ; Johnson, Donna D. ; Saade, George ; Lewis, David F. ; Robinson, Christopher ; Danoff, Theodore M. ; Chauhan, Nikhil ; Hopoate-Sitake, Moana ; Porter, Kathy B. ; Humphrey, Rachel G. ; Trofatter, Kenneth F. ; Amon, Erol ; Ward, Suzanne ; Kennedy, Lizbeth ; Mason, Lorrie ; Johnston, J. Andrew. / Digoxin immune fab treatment for severe preeclampsia. In: American Journal of Perinatology. 2010 ; Vol. 27, No. 8. pp. 655-662.
@article{41be6db4eb90472999e84122ff342a34,
title = "Digoxin immune fab treatment for severe preeclampsia",
abstract = "We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF (n=24) or placebo (n=27) for 48 hours. Primary outcomes were change in creatinine clearance (CrCl) at 24 to 48 hours and antihypertensive drug use. Serum sodium pump inhibition, a sequela of endogenous digitalis-like factors (EDLF), was also assessed. CrCl in DIF subjects was essentially unchanged from baseline versus a decrease with placebo (310 and 3410 mL/min, respectively, p=0.02). Antihypertensive use was similar between treatments (46 and 52{\%}, respectively, p=0.7). Serum sodium pump inhibition was decreased with DIF compared with placebo at 24 hours after treatment initiation (least squares mean difference, 19 percentage points, p=0.03). DIF appeared to be well tolerated. These results suggest DIF prevents a decline in renal function in severe preeclampsia by neutralizing EDLF. Sodium pump inhibition was significantly improved. Further research is warranted.",
keywords = "Digoxin immune Fab, endogenous digitalis-like factors, preeclampsia, sodium pump",
author = "Adair, {C. David} and Buckalew, {Vardaman M.} and Graves, {Steven W.} and Lam, {Garrett K.} and Johnson, {Donna D.} and George Saade and Lewis, {David F.} and Christopher Robinson and Danoff, {Theodore M.} and Nikhil Chauhan and Moana Hopoate-Sitake and Porter, {Kathy B.} and Humphrey, {Rachel G.} and Trofatter, {Kenneth F.} and Erol Amon and Suzanne Ward and Lizbeth Kennedy and Lorrie Mason and Johnston, {J. Andrew}",
year = "2010",
doi = "10.1055/s-0030-1249762",
language = "English (US)",
volume = "27",
pages = "655--662",
journal = "American Journal of Perinatology",
issn = "0735-1631",
publisher = "Thieme Medical Publishers",
number = "8",

}

TY - JOUR

T1 - Digoxin immune fab treatment for severe preeclampsia

AU - Adair, C. David

AU - Buckalew, Vardaman M.

AU - Graves, Steven W.

AU - Lam, Garrett K.

AU - Johnson, Donna D.

AU - Saade, George

AU - Lewis, David F.

AU - Robinson, Christopher

AU - Danoff, Theodore M.

AU - Chauhan, Nikhil

AU - Hopoate-Sitake, Moana

AU - Porter, Kathy B.

AU - Humphrey, Rachel G.

AU - Trofatter, Kenneth F.

AU - Amon, Erol

AU - Ward, Suzanne

AU - Kennedy, Lizbeth

AU - Mason, Lorrie

AU - Johnston, J. Andrew

PY - 2010

Y1 - 2010

N2 - We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF (n=24) or placebo (n=27) for 48 hours. Primary outcomes were change in creatinine clearance (CrCl) at 24 to 48 hours and antihypertensive drug use. Serum sodium pump inhibition, a sequela of endogenous digitalis-like factors (EDLF), was also assessed. CrCl in DIF subjects was essentially unchanged from baseline versus a decrease with placebo (310 and 3410 mL/min, respectively, p=0.02). Antihypertensive use was similar between treatments (46 and 52%, respectively, p=0.7). Serum sodium pump inhibition was decreased with DIF compared with placebo at 24 hours after treatment initiation (least squares mean difference, 19 percentage points, p=0.03). DIF appeared to be well tolerated. These results suggest DIF prevents a decline in renal function in severe preeclampsia by neutralizing EDLF. Sodium pump inhibition was significantly improved. Further research is warranted.

AB - We evaluated the efficacy, safety, and biological mechanisms of digoxin immune Fab (DIF) treatment of severe preeclampsia. Fifty-one severe preeclamptic patients were randomized in double-blind fashion to DIF (n=24) or placebo (n=27) for 48 hours. Primary outcomes were change in creatinine clearance (CrCl) at 24 to 48 hours and antihypertensive drug use. Serum sodium pump inhibition, a sequela of endogenous digitalis-like factors (EDLF), was also assessed. CrCl in DIF subjects was essentially unchanged from baseline versus a decrease with placebo (310 and 3410 mL/min, respectively, p=0.02). Antihypertensive use was similar between treatments (46 and 52%, respectively, p=0.7). Serum sodium pump inhibition was decreased with DIF compared with placebo at 24 hours after treatment initiation (least squares mean difference, 19 percentage points, p=0.03). DIF appeared to be well tolerated. These results suggest DIF prevents a decline in renal function in severe preeclampsia by neutralizing EDLF. Sodium pump inhibition was significantly improved. Further research is warranted.

KW - Digoxin immune Fab

KW - endogenous digitalis-like factors

KW - preeclampsia

KW - sodium pump

UR - http://www.scopus.com/inward/record.url?scp=77955528215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955528215&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1249762

DO - 10.1055/s-0030-1249762

M3 - Article

C2 - 20232280

AN - SCOPUS:77955528215

VL - 27

SP - 655

EP - 662

JO - American Journal of Perinatology

JF - American Journal of Perinatology

SN - 0735-1631

IS - 8

ER -